The Role of Stress, Glucocorticoids & Β-Adrenergic

Total Page:16

File Type:pdf, Size:1020Kb

The Role of Stress, Glucocorticoids & Β-Adrenergic University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Spring 2011 The Role of Stress, Glucocorticoids & β-Adrenergic Signaling in Aversive, Hippocampus-Dependent Memory Retrieval Keith B. Schutsky University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Schutsky, Keith B., "The Role of Stress, Glucocorticoids & β-Adrenergic Signaling in Aversive, Hippocampus-Dependent Memory Retrieval" (2011). Publicly Accessible Penn Dissertations. 990. https://repository.upenn.edu/edissertations/990 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/990 For more information, please contact [email protected]. The Role of Stress, Glucocorticoids & β-Adrenergic Signaling in Aversive, Hippocampus-Dependent Memory Retrieval Abstract Studies in wild-type rats and mice, and mutant mice lacking norepinephrine (NE) demonstrate that NE, β1-adrenergic, cAMP/PKA and Epac signaling are required for intermediate-term hippocampus-dependent memory retrieval. Although it has been proposed that glucocorticoids (GCs) facilitate β-adrenergic signaling to impair retrieval, neither a specific equirr ement for NE nor a definitive mechanism as to how this interaction occurs has been established. This thesis provides compelling evidence that 1) GCs do not require (but can synergize with) the adrenergic system to impair hippocampus-dependent memory retrieval; 2) GCs and xamoterol interact with the β2 receptor to impair retrieval; 3) β2 receptors signal through Gi/o in the hippocampus to impair retrieval, acting to negate the facilitation of hippocampus- dependent memory retrieval mediated by β1-Gs signaling; 4) GCs impair retrieval through possibly direct interaction with the β2 receptor; 5) β2 signaling is required for retrieval and may be required for short-term maintenance of fear memory; 6) β3 signaling influences etrier val; 7) interactions between β receptors are important and net effects of β receptor stimulation (or antagonism) on hippocampal cAMP signaling likely determine the degree of retrieval impairment expressed, as individual β receptors can have similar or opposing effects on cAMP levels; and 8) adrenergic and glucocorticoid influences on etrier val are limited by the age of the memory. Degree Type Dissertation Degree Name Doctor of Philosophy (PhD) Graduate Group Pharmacology First Advisor Steven A. Thomas Keywords stress, glucocorticoids, norepinephrine, beta-adrenergic receptor, fear memory retrieval, hippocampus Subject Categories Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/990 THE ROLE OF STRESS, GLUCOCORTICOIDS & -ADRENERGIC SIGNALING IN AVERSIVE, HIPPOCAMPUS-DEPENDENT MEMORY RETRIEVAL Keith Schutsky A Dissertation in Pharmacology Presented to the Faculties of the University of Pennsylvania in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy 2011 Supervisor of Dissertation Supervisor Signature _______________________________________________________________ Dr. Steven A. Thomas, M.D., Ph.D., Associate Professor of Pharmacology Graduate Group Chairperson Signature_______________________________________________________________ Dr. Vladimir Muzykantov, M.D., Ph.D., Associate Professor of Pharmacology and Medicine Dissertation Committee Dr. Judith Meinkoth, Ph.D., Associate Professor of Pharmacology Dr. Edwin Abel, III, Ph.D., Brush Family Professor of Biology Dr. Julie Blendy, Ph.D., Associate Professor of Pharmacology Dr. Benoit Giasson, Ph.D., Assistant Professor of Pharmacology DEDICATION To my wife, Tina, for her love, strength and support. ii ACKNOWLEDGEMENTS I am extremely grateful to Dr. Steven Thomas for giving me the opportunity join his research group, and I am privileged to have studied under his guidance. He has supported me in every aspect of the scientific process - in forming hypotheses, designing experiments, analyzing results, writing and submitting papers for publication. His mentorship and tireless efforts have enabled me to prosper as an independent-thinking scientist and prepared me to face obstacles that may lie ahead in my career. I want to give special thanks to Ming Ouyang, Sung-Ha Jin and Hong-Mei Luo for their technical expertise and for taking the time to train me. I must acknowledge current lab members, Christina Castelino and Lei Zhang for assistance with experiments and past lab members for their friendship and support. I want to thank my thesis committee members, Dr. Judith Meinkoth, Dr. Ted Abel, Dr. Julie Blendy and Dr. Benoit Giasson for their helpful suggestions to maintain progress in my research and for strengthening my ability to answer questions concerning my research, its implications and its limitations. I must acknowledge my family and friends for their encouragement and wisdom. Most importantly, I want to thank my wife, Tina and my two children, Jake and Logan for their unconditional love and for helping me realize the things in life that are truly important. iii ABSTRACT THE ROLE OF STRESS, GLUCOCORTICOIDS & -ADRENERGIC SIGNALING IN AVERSIVE, HIPPOCAMPUS-DEPENDENT MEMORY RETRIEVAL Keith Schutsky Steven A. Thomas Studies in wild-type rats and mice, and mutant mice lacking norepinephrine (NE) demonstrate that NE, 1-adrenergic, cAMP/PKA and Epac signaling are required for intermediate-term hippocampus-dependent memory retrieval. Although it has been proposed that glucocorticoids (GCs) facilitate-adrenergic signaling to impair retrieval, neither a specific requirement for NE nor a definitive mechanism as to how this interaction occurs has been established. This thesis provides compelling evidence that 1) GCs do not require (but can synergize with) the adrenergic system to impair hippocampus-dependent memory retrieval; 2) GCs and xamoterol interact with the 2 receptor to impair retrieval; 3) 2 receptors signal through Gi/o in the hippocampus to impair retrieval, acting to negate the facilitation of hippocampus-dependent memory retrieval mediated by 1-Gs signaling; 4) GCs impair retrieval through possibly direct interaction with the 2 receptor; 5) signaling is required for retrieval and may be required for short-term maintenance of fear memory; 6) signaling influences retrieval; 7) interactions between receptors are important and net effects of receptor stimulation (or antagonism) on hippocampal cAMP signaling likely determine the degree of retrieval impairment expressed, as individual receptors can have similar or opposing effects on iv cAMP levels; and 8) adrenergic and glucocorticoid influences on retrieval are limited by the age of the memory. v TABLE OF CONTENTS Dedication ............................................................................................. ii Acknowledgements.............................................................................. iii Abstract ................................................................................................ iv Table of Contents ................................................................................. vi List of Tables ...................................................................................... xii List of Figures .................................................................................... xiii Abbreviations ...................................................................................... xv Chapter 1: Introduction 1.1 Memory Types & Importance of Hippocampus in Episodic Memory ..............2 1.2 Strength of Memory is Influenced by Environment and Emotional State .........3 1.3 Animal Models of Fear Memory & Brain Structures Involved 1.3.1 Auditory (Cued) Fear Conditioning ....................................................4 1.3.2 Contextual Fear Conditioning .............................................................5 1.3.3 Inhibitory (Passive Avoidance) ...........................................................7 1.3.4 Spatial Navigation ...............................................................................9 1.4 Role of NE/E & -adrenergic Signaling in Fear Memory 1.4.1 Epinephrine & Enhanced Consolidation ...........................................10 1.4.2 Norepinephrine & Enhanced Consolidation .....................................11 1.4.3 NE/E is not Required for Fear Memory Consolidation ....................12 1.4.4 Signaling is not Required for Fear Memory Consolidation ...........13 1.4.5 NE/E is Required for Intermediate-term Memory Retrieval vi 1.4.5.1 NE/E and Spatial Retrieval ...................................................14 1.4.5.2 NE/E and Contextual Memory Retrieval ..............................14 1.4.6 Signaling is Required for Intermediate-term Memory Retrieval 1.4.6.1 Signaling and Spatial Retrieval .........................................15 1.4.6.2 1 Signaling and Contextual Memory Retrieval ...................16 1.4.6.3 2 & 3 Receptors Influence Retrieval Independently & in Concert with 1 .........................................................................17 1.5 Role of Stress & Glucocorticoids in Fear Memory 1.5.1 Stress, Glucocorticoids (GCs) & Consolidation ...............................18 1.5.2 Stress, GCs & Retrieval ....................................................................18 1.6 Interactions between Adrenergic & GC Signaling in Fear Memory 1.6.1 NE/E, Receptor & GC
Recommended publications
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Modulation of Dialysate Levels of Dopamine, Noradrenaline
    Modulation of Dialysate Levels of Dopamine, Noradrenaline, and Serotonin (5-HT) in the Frontal Cortex of Freely-Moving Rats by (-)-Pindolol Alone and in Association with 5-HT Reuptake Inhibitors: Comparative Roles b of -Adrenergic, 5-HT1A, and 5-HT1B Receptors Alain Gobert, Ph.D. and Mark J. Millan, Ph.D. (-)-Pindolol, which possesses significant affinity for 5-HT1A, involved. (-)-Pindolol potentiated the increase in FCX levels b 5-HT1B, and 1/2-adrenergic receptors (AR)s, dose- of 5-HT elicited by the 5-HT reuptake inhibitors, fluoxetine dependently increased extracellular levels of dopamine and duloxetine, and also enhanced their ability to elevate (DA) and noradrenaline (NAD) versus 5-HT, in dialysates FCX levels of DA—though not of NAD. In contrast to of the frontal cortex (FCX), but not accumbens and (-)-pindolol, betaxolol and ICI118,551 did not affect the striatum, of freely-moving rats. In distinction, the actions of fluoxetine, whereas both WAY100,635 and b preferential 1-AR antagonist, betaxolol, and the SB224,289 potentiated the increase in levels of 5-HT—but b preferential 2-AR antagonist, ICI118,551, did not increase not DA or NAD levels—elicited by fluoxetine. In basal levels of DA, NAD, or 5-HT. Further, they both dose- conclusion, (-)-pindolol modulates, both alone and together dependently and markedly blunted the influence of with 5-HT reuptake inhibitors, dopaminergic, adrenergic, (-)-pindolol upon DA and NAD levels. The selective 5-HT1A and serotonergic transmission in the FCX via a complex b receptor antagonist, WAY100,635, slightly attenuated the pattern of actions at 1/2-ARs, 5-HT1A, and 5-HT1B (-)-pindolol-induced increase in DA and NAD levels, while receptors.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Β2 Adrenergic Agonist Suppresses Eosinophil-Induced Epithelial-To- Mesenchymal Transition of Bronchial Epithelial Cells Keigo Kainuma1,2, Tetsu Kobayashi3, Corina N
    Kainuma et al. Respiratory Research (2017) 18:79 DOI 10.1186/s12931-017-0563-4 RESEARCH Open Access β2 adrenergic agonist suppresses eosinophil-induced epithelial-to- mesenchymal transition of bronchial epithelial cells Keigo Kainuma1,2, Tetsu Kobayashi3, Corina N. D’Alessandro-Gabazza2, Masaaki Toda2, Taro Yasuma2, Kota Nishihama2, Hajime Fujimoto3, Yu Kuwabara1,2, Koa Hosoki1,2, Mizuho Nagao1, Takao Fujisawa1 and Esteban C. Gabazza2* Abstract Background: Epithelial-mesenchymal transition is currently recognized as an important mechanism for the increased number of myofibroblasts in cancer and fibrotic diseases. We have already reported that epithelial- mesenchymal transition is involved in airway remodeling induced by eosinophils. Procaterol is a selective and full β2 adrenergic agonist that is used as a rescue of asthmatic attack inhaler form and orally as a controller. In this study, we evaluated whether procaterol can suppress epithelial-mesenchymal transition of airway epithelial cells induced by eosinophils. Methods: Epithelial-mesenchymal transition was assessed using a co-culture system of human bronchial epithelial cells and primary human eosinophils or an eosinophilic leukemia cell line. Results: Procaterol significantly inhibited co-culture associated morphological changes of bronchial epithelial cells, decreased the expression of vimentin, and increased the expression of E-cadherin compared to control. Butoxamine, a specific β2-adrenergic antagonist, significantly blocked changes induced by procaterol. In addition, procaterol inhibited the expression of adhesion molecules induced during the interaction between eosinophils and bronchial epithelial cells, suggesting the involvement of adhesion molecules in the process of epithelial-mesenchymal transition. Forskolin, a cyclic adenosine monophosphate-promoting agent, exhibits similar inhibitory activity of procaterol. Conclusions: Overall, these observations support the beneficial effect of procaterol on airway remodeling frequently associated with chronic obstructive pulmonary diseases.
    [Show full text]
  • Ep 2626065 A1
    (19) TZZ Z_T (11) EP 2 626 065 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: A61K 31/137 (2006.01) A61K 31/135 (2006.01) 14.08.2013 Bulletin 2013/33 A61K 31/4704 (2006.01) A61K 31/58 (2006.01) A61K 31/56 (2006.01) A61K 9/12 (2006.01) (2006.01) (2006.01) (21) Application number: 11827927.2 A61K 9/14 A61P 11/06 (86) International application number: Date of filing: 01.02.2011 (22) PCT/CN2011/070883 (87) International publication number: WO 2012/041031 (05.04.2012 Gazette 2012/14) (84) Designated Contracting States: (72) Inventor: WU, Wei-hsiu AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Taiwan (TW) PL PT RO RS SE SI SK SM TR (74) Representative: Patentanwaltskanzlei WILHELM (30) Priority: 28.09.2010 CN 201010502339 & BECK Prinzenstrasse 13 (71) Applicant: Intech Biopharm Ltd. 80639 München (DE) Taipei (TW) (54) COMPOUND COMPOSITION FOR INHALATION USED FOR TREATING ASTHMA (57) An inhaled pharmaceutical composition con- tric way as a controller. The eccentric way control therapy tains primary active ingredients of beta2- agonist and cor- could create a low blood concentration period during the ticosteroids.The pharmaceuticalcompositions disclosed day and minimize the acute tolerance phenomenon (or in the present invention are to be inhaled by a patient so called tachyphylaxis) for bronchodilator - beta2-ago- when needed as a reliever, or administrated in an eccen- nists in treating asthma or other obstructive respiratory disorders.
    [Show full text]
  • Clenbuterol Elisa Kit Instructions Product #101219 & 101216 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology CLENBUTEROL ELISA KIT INSTRUCTIONS PRODUCT #101219 & 101216 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Clenbuterol and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Clenbuterol ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug- enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]
  • Table of Contents (PDF)
    1 , I..,U i + i !, , i HearBritish Br Heart J: first published as on 1 July 1985. Downloaded from monthly journal of cardiology blished in association with eBritish Cardiac Society Journal m Editorial: strategies for preventing and screening 1 Functionless retained pacing leads in the for coronary heart disease MF Oliver cardiovascular system: a complication of Myocardial infarction and thrombolysis: pacemaker treatment FZerbe, A Ponizynski, electrocardiographic short term and long term WDyszkiewicz, A Ziemiahski, TDzi~gielewski, results using precordial mapping R von Essen, HKrug 76 WSchmidt, R Uebis, B Edelmann, S Effert, J Silny, G Rau 6 Effect of exercise on ventricular response to atrial Rupture of the myocardium: occurrence and risk fibrillation in Wolff-Parkinson-White factors MDellborg, P Held, KSwedberg, A Vedin 1 syndrome JCPCrick, D WDavies, PHolt, P V L Curry, ESowton 80 Effect of xamoterol (ICI 1 1 8587), a new beta, adrenoceptor partial agonist, on resting Intravenous sotalol for the treatment of atrial http://heart.bmj.com/ haemodynamic variables and exercise tolerance in fibrillation and flutter after cardiopulmonary patients with left ventricular dysfunction bypass: comparison with disopyramide and A O Molajo, D HBennett 17 digoxin in a randomised trial TJCampbell, How important is a history of chest pain in TP Gavaghan, JJ Morgan 86 determining the degree of ischaemia in patients Factors relating to the development of with angina pectoris? A A Quyyumi, CM Wright, hypertension after cardiopulmonary bypass L J Mockus, K M Fox 22 TTJ Cooper, TH Clutton-Brock, SNJones, J Tinker, Ischaemic heart disease and prodromes of sudden T Treasure 91 cardiac death: is it possible to identify high risk on October 2, 2021 by guest.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Emea/666243/2009
    European Medicines Agency London, 29 October 2009 EMEA/666243/2009 ISSUE NUMBER: 0910 MONTHLY REPORT PHARMACOVIGILANCE WORKING PARTY (PHVWP) OCTOBER 2009 PLENARY MEETING The CHMP Pharmacovigilance Working Party (PhVWP) held its October 2009 plenary meeting on 19-21 October 2009. PhVWP DISCUSSIONS ON SAFETY CONCERNS Below is a summary of the discussions regarding non-centrally authorised medicinal products in accordance with the PhVWP publication policy (see under http://www.emea.europa.eu/htms/human/phv/reports.htm). Positions agreed by the PhVWP for non- centrally authorised products are recommendations to Member States. For safety updates concerning centrally authorised products and products subject to ongoing CHMP procedures, readers are referred to the CHMP Monthly Report (see under http://www.emea.europa.eu/pressoffice/presshome.htm). The PhVWP provides advice on these products to the Committee of Medicinal Products for Human Use (CHMP) upon its request. Antipsychotics - risk of venous thromboembolism (VTE) Identify risk factors for VTE for preventive action before and during treatment with antipsychotics The PhVWP completed their review on the risk of VTE of antipsychotics1. The review was triggered by and based on data from the UK spontaneous adverse drug reactions reporting system and the published literature. The PhVWP carefully considered the data, including the limitations of both information sources, such as the lack of randomised controlled trial data, the heterogeneity of published studies and the potential confounding factors such as sedation and weight gain, commonly present in antipsychotic users. The PhVWP concluded that an association between VTE and antipsychotics cannot be excluded. Distinguishing different risk levels between the various active substances was not possible.
    [Show full text]
  • Desensitization and Selective Down-Regulation of Rat Cardiac '31-Adrenoceptors by Prolonged in Vivo Infusion of T-0509, a 81-Adrenoceptor Full Agonist
    Desensitization and Selective Down-Regulation of Rat Cardiac '31-Adrenoceptors by Prolonged In Vivo Infusion of T-0509, a 81-Adrenoceptor Full Agonist Yoji Sato', Satomi Adachi-Akahane', Pablo Prados2, Kazuhiro Imai2 and Taku Nagao'°* 'Departmentof Toxicologyand Pharmacologyand 2Departmentof AnalyticalChemistry , Facultyof PharmaceuticalSciences, Universityof Tokyo,Hongo, Bunkyo-ku,Tokyo 113, Japan ReceivedJune 13, 1995 AcceptedSeptember 18, 1995 ABSTRACT-We studied the effects of prolonged infusion of a selective ~1-adrenoceptor (f3,AR) full agonist, T-0509 [(-)-(R)-1-(3,4-dihydroxyphenyl)-2-[(3,4-dimethoxyphenethyl)amino]ethanol hydrochlo- ride], with regard to its inotropic effect in vivo and cardiac (3AR density. The results were compared with those for isoproterenol. Continuous infusion of isoproterenol at doses of 2.5-40 ,ug/kg/hr, s.c. for 6 days shifted the dose-response curves of isoproterenol (i.v.) for LVdP/dtmx to the right and increased the ED50 values up to fourfold. Isoproterenol infusion at 40 pg/kg/hr reduced the density of both r3,- and ~2ARs by 36010and 43070 respectively, in left ventricular membranes. Following 6-day infusion of T-0509 at doses sufficient to induce a positive inotropic effect (5-40 rig/kg/hr), the ED50 value of T-0509 (i.v.) for LVdP/dtmax was also increased up to fourfold. In contrast to isoproterenol, infusion of T-0509 caused selective down-regulation of (3,ARs by 30% without changing the number of hARs. These results indicate that long-term application of a selective /31AR full agonist causes desensitization to its inotropy in vivo, with subtype-selective down-regulation of ~1ARs in cardiac ventricles.
    [Show full text]
  • The Effects of Dobutamine on Cardiac Sympathetic Activity in Patients with Congestive Heart Failure Abdul Al-Hesayen, MD, Eduardo R
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 39, No. 8, 2002 © 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01783-7 The Effects of Dobutamine on Cardiac Sympathetic Activity in Patients With Congestive Heart Failure Abdul Al-Hesayen, MD, Eduardo R. Azevedo, MD, Gary E. Newton, MD, John D. Parker, MD, FACC Toronto, Canada OBJECTIVES The goal of this work was to study the effects of short-term infusion of dobutamine on efferent cardiac sympathetic activity. BACKGROUND Increased efferent cardiac sympathetic activity is associated with poor outcomes in the setting of congestive heart failure (CHF). Dobutamine is commonly used in the therapy of decompensated CHF. Dobutamine, through its effects on excitatory beta-receptors, may increase cardiac sympathetic activity. METHODS Seven patients with normal left ventricular (LV) function and 13 patients with CHF were studied. A radiotracer technique was used to measure cardiac norepinephrine spillover (CANESP) before and during an intravenous infusion of dobutamine titrated to increase the rate of rise in LV peak positive pressure (ϩdP/dt) by 40%. RESULTS Systemic arterial pulse pressure increased significantly in response to dobutamine in the normal LV function group (74 Ϯ 3mmHgto85Ϯ 3 mm Hg, p ϭ 0.005) but remained unchanged in the CHF group. Dobutamine caused a significant decrease in LV end-diastolic pressure in the CHF group (14 Ϯ 2mmHgto11Ϯ 2 mm Hg, p ϭ 0.02), an effect not observed in the normal LV group.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://edhub.ama-assn.org/ on 09/24/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]